Evidence map›Paper›PMID 39434433›Full record

ArticleAdvanced healthcare materials2024

In Vitro Sonodynamic Therapy Using a High Throughput 3D Glioblastoma Spheroid Model with 5-ALA and TMZ Sonosensitizers.

Priyankan Datta, Nan Sook Lee, Sreejesh Moolayadukkam, Rakesh P Sahu, Xi Yu, Tianze Guo, Qifa Zhou, Y Wang, Ishwar K Puri

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Hydrogel Microdroplet Based Glioblastoma Drug Screening Platform.Journal of biomedical materials research. Part A · 2026
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Priyankan DattaDepartment of Aerospace and Mechanical Engineering, University of Southern California, Los Angeles, CA, 90089, USA.ORCID 0000-0002-2899-6714
Nan Sook LeeAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, 90089, USA.
Sreejesh MoolayadukkamDepartment of Aerospace and Mechanical Engineering, University of Southern California, Los Angeles, CA, 90089, USA.
Rakesh P SahuDepartment of Mechanical Engineering, McMaster University, Hamilton, ON, L8S 4L8, Canada.
Xi YuAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, 90089, USA.
Tianze GuoAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, 90089, USA.
Qifa ZhouAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, 90089, USA.
Y WangAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, 90089, USA.
Ishwar K PuriDepartment of Aerospace and Mechanical Engineering, University of Southern California, Los Angeles, CA, 90089, USA.ORCID 0000-0002-8713-4188

Funding

Ultrasensitive kinase biosensors for multiplex imaging of coordinated spatiotemporal signaling in cancer-immune interactionsR01CA262815 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Yingxiao Wang, Jin Zhang · 2022 to 2026
$3.3M
Acoustothermogenetics for Cell EngineeringR35GM140929 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI WANG, YINGXIAO · 2021 to 2025
$2.9M
Ultrasound-controlled remote activation of CAR T cells for localized tumor immunotherapyR01EB029122 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI WANG, YINGXIAO · 2020 to 2023
$1.7M
NCI NIH HHS R01 CA262815NIBIB NIH HHS EB029122NIBIB NIH HHS R01 EB029122NIGMS NIH HHS R35 GM140929NIH HHS CA262815NIH HHS GM140929
6 · The paper itself

Abstract

Sonodynamic therapy (SDT) administered using low-intensity pulsed ultrasound and sonosensitizers is an emerging, minimally invasive, targeted deep-tissue therapy for solid tumors such as glioblastoma multiforme (GBM). Initial clinical trials show promising outcomes for SDT treatments of GBM. A crucial aspect of SDT is the sonosensitizer that interacts with ultrasound, facilitating energy transfer to the tumor, thus inducing therapeutic efficacy. Current in vitro methods for determining the therapeutic efficacies of sonosensitizers are time-consuming and expensive. A novel high-throughput magnetically printed 3D GBM model is used to overcome this challenge. The hypothesis is that the use of two sonosensitizers, one a chemotherapeutic drug, enhances SDT efficacy through their additive chemical interactions. The GBM model is used to evaluate the effectiveness of two sonosensitizer molecules, 5-aminolevulinic acid (5-ALA) and theU.S. Food and Drug Administration (FDA)-approved chemotherapeutic drug Temozolomide (TMZ). It is confirmed that implement high-throughput GBM models to evaluate sonosensitizer combinations and their efficacies is feasible and, for the first time, show that the combined effect of both sensitizers, 5-ALA and TMZ, is superior for preventing spheroid growth than employing each molecule separately. This finding is relevant for future clinical trials of GBM treatment with SDT.

Indexed as

Aminolevulinic AcidGlioblastomaSpheroids, CellularTemozolomideUltrasonic TherapyBrain NeoplasmsCell Line, TumorCell SurvivalHumansAminolevulinic AcidTemozolomide5‐ALAGlioblastomahigh‐throughput spheroid platformSonodynamic therapyTMZ

Identifiers

PMID39434433
PMCPMC11670275

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.